Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

This transaction was a mandatory sale to cover tax obligations associated with the vesting of restricted stock units (RSUs), as stipulated by Scholar Rock's equity incentive plans. These RSUs were ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

The transaction comes as Scholar Rock, now valued at $4.19 billion ... The company is also expanding the use of apitegromab into other rare neuromuscular conditions and advancing its ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...